• Alvotech is trading 3.09% up at ISK 668.00 today after announcing the first known worldwide regulatory submission for AVT29, its proposed biosimilar to Eylea® 8 mg.
  • The European application was submitted on October 14, 2026, in partnership with Advanz Pharma.
  • AVT29 aims to provide a high-dose aflibercept biosimilar, potentially reducing treatment frequency for patients with retinal diseases.